Non-Invasive FFR Gets Boost from Medtronic

FFRangio was developed by CathWorks, an Israeli company, and was approved by the US FDA in 2018, and a year later by the Ministry of Health, Labour and Welfare in Japan. The pivotal study that led to FDA approval, FAST-FFR, showed that angiography-derived FFR was highly accurate when compared with pressure-wire FFR. This week Medtronic announced that it was investing $75 million in the company, co-promoting its use, and has an option to acquire CathWorks for $585 million, once certain milestones are met.

http://www.ptca.org/news/2022/0717_MEDTRONIC_CATHWORKS.html

Source: News from Angioplasty.Org - July 17, 2022 Category: Cardiology Source Type: news